Intended for US audiences only.

Primary Immunodeficiency Therapy on Your Terms

Cutaquig is used to treat adults and pediatric patients 2 years of age and older with primary immunodeficiency (PI) disease. There are many forms of PI. The most common types lead to an inability to make a very important kind of protein called antibodies, which protect your body against infections.1 As a ready-to-use liquid solution containing immunoglobulin G—also known as IgG—cutaquig is made from human plasma donated by healthy people.1,2 It contains the antibodies you may be missing.1 Regular use of cutaquig will help your body to fight bacteria and viruses that cause infections.1,2


Cutaquig is a subcutaneous immunoglobulin therapy (or SCIg).1 With SCIg, you infuse cutaquig under the skin instead of into a vein (infusing medication for PI into a vein is known as intravenous immunoglobulin therapy, or IVIg).1 Once you’ve been trained by your healthcare provider, you’ll have the option to self-administer cutaquig.1 Like most patients who choose to self-administer, you may gain a greater sense of freedom. Plus, cutaquig offers convenience—you may be able to self-administer almost anywhere, including home, work, or school.3-5


Cutaquig offers proven safety.1,5 The donated plasma from which it is made is rigorously tested to ensure purity and safety. With cutaquig therapy, there is a low rate of side effects—mostly local infusion site reactions, including but not limited to redness, swelling, and itching.1,5 In a clinical study, most of the site reactions were mild or moderate.5


In clinical studies, adults and pediatric patients 2 years and older taking cutaquig had low overall rates of infection, with zero serious bacterial infections in a phase 3 clinical trial.1,5,6 In addition, patients taking cutaquig experienced a low rate of absences from work or school due to infection.1,6


1. Cutaquig Full Prescribing Information. Paramus, NJ: Octapharma; rev October 2021.

2. Clinical Study Report SCGAM-01. Clinical Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability and safety of subcutaneous human immunoglobulin (octanorm 16.5%) in patients with primary immunodeficiency diseases. NCT01888484. June 2018. Accessed April 26, 2019.

3. McCormack PL. Immune globulin subcutaneous (human) 20% in primary immunodeficiency disorders. Drugs. 2012;72(8):1087-1097.

4. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277-287.

5. Kobayashi RH, Gupta S, Melamed I, et al. Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies. Front Immunol. 2019;10(40):1-12.

6. Kobayashi RH, Mandujano JF, Rehman SM, et al. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]). Immunotherapy. 2021;13(10):813 -824.

Indications and Important Safety Information for cutaquig® (Immune Globulin Subcutaneous [Human]– hipp, 16.5% solution)
See the cutaquig full prescribing information for complete boxed warning
Thrombosis may occur with immune globulin products, including cutaquig.